Angelini ventures invests in an American startup for new anti-epilepsy technology

Angelini Ventures, international venture capital company of Angelini Industries, has invested 6 million dollars in Cadence Neuroscience, an American start-up that is developing, in collaboration with researchers of the Mayo Clinic, a new neuro-therapymodulation for the treatment of drug-resistant focal epilepsy in children and adults. It is based on software capable of capturing within the EEG pathway, the signals associated with epilepsy and counteract them with timely electrical stimulation aimed at eliminating or reducing seizures.
The company announces how the six million dollars invested by Angelini Ventures are part of the new total funding of 26 million dollars, which represents the “round of series B”, or the second phase of growth of Cadence Neuroscience, aimed at completing preliminary clinical trials and obtaining the approval of the Food and Drug Administration (FDA). The round was carried out by Angelini Lumira Bioscience Fund (the North American fund created by Lumira Ventures and Angelini Ventures) and saw the participation of other new investors: F-Prime Capital, LivaNova PLC, Angelini Ventures, Spectrum Financial Services and Mayo Clinic, together with JAZZ Venture Partners who had led the initial “A series round“. Gerry Brunk of Lumira Ventures and Kevin Chu of F-Prime Capital joins the board of directors of Cadence Neuroscience.

«Investments like this, which we are carrying out with Angelini Ventures – comments Sergio Marullo di Condojanni, CEO of Angelini Industries – are fully part of our growth strategy in the therapeutic area of neurological disorders and are in perfect harmony with what is the long-term vision that an entrepreneurial group like ours carries in its DNA. In addition to being a potential opportunity in terms of development, this participation also fully responds to our mission, which is primarily to take care of patients and the quality of their lives».
«The technology developed by Cadence Neuroscience has the potential to become a reference point for the treatment of drug-resistant epilepsy and other diseases that affect the brain», observes Paolo Di Giorgio, CEO of Angelini Ventures – «This investment is part of our strategy to focus internationally on innovative realities and high technological content in the areas of life sciences, digital health and biotechnology, to identify, financing and implementing solutions that innovate traditional healthcare models».

With investments of 300 million euros, of which 70 already planned, in Europe, North America and Israel, with particular attention to brain health and market segments aimed at women, Angelini Ventures is part of the growth and innovation strategy of Angelini Industries, a multinational industrial group with 5,800 employees and revenues of 2 billion euros in the health, consumer, industrial technology sectors.

Cadence Neuroscience is a start-up in Redmond, near Seattle, founded in 2017, which has developed a new technology for the treatment of focal drug-resistant epilepsy, in childhood and adulthood based on research by the neurology and neurosurgery team of the Mayo Clinic led by the neurologist, epilepsy expert, Gregory Worrell.

Cadence Neuroscience has developed a software that can detect, within the electroencephalogram path, precise signals connected to epilepsy and modulate them through precise electrical impulses with the aim of eliminating or reducing seizures. The software is installed inside a small permanent neural implant that generates a continuous electrical cortical stimulation that is calibrated precisely based on the brain impulses monitored by the software itself. In this sense, the system developed by Cadence Neuroscience aims to offer a targeted and personalized therapy.

English translation from the Italian newspaper Sanita33, published by Edra S.p.A;